

1 **Rapid comparative evaluation of SARS-CoV-2 rapid point-of-care antigen tests**

2

3 Anna Denzler^{1, †}, Max L. Jacobs^{1, †}, Victoria Witte¹, Paul Schnitzler², Claudia M.
4 Denkinger^{3,*}, Michael Knop^{1,4,5,*}

5

6 **Affiliations:**

7 ¹ Center for Molecular Biology of Heidelberg University (ZMBH), Heidelberg,
8 Germany.

9 ² Department of Infectious Diseases, Virology, Heidelberg University Hospital,
10 Heidelberg, Germany.

11 ³ Department of Infectious Diseases, Division of Tropical Medicine, Heidelberg
12 University Hospital, Heidelberg, Germany.

13 ⁴ German Cancer Research Center (DKFZ), Heidelberg, Germany.

14 ⁵ DKFZ-ZMBH Alliance, Heidelberg, Germany.

15 * Corresponding authors.

16 † These authors contributed equally to this work.

17

18 **Keywords:** Comparison of Antigen-detecting rapid diagnostic test; COVID-19;
19 SARS-CoV-2; Testing sensitivity, non-functional AgPOC tests.

20

21

22 **Corresponding authors:**

23 Michael Knop

24 Center for Molecular and Cellular Biology Heidelberg, Heidelberg University,
25 Heidelberg, Germany

26 m.knop@zmbh.uni-heidelberg.de

27 +49 6221 54 4213

28 Claudia M. Denkinger

29 Division of Tropical Medicine, Center for Infectious Diseases, Heidelberg University
30 Hospital, Heidelberg, Germany

31 Claudia.Denkinger@uni-heidelberg.de

32 +49 6221 56 36637

33 **Abstract**

34 **Background:** Currently, more than 500 different AgPOCTs for SARS-CoV-2
35 diagnostics are on sale (July 2021), for many of which no data about sensitivity other
36 than self-acclaimed values by the manufacturers are available. In many cases these
37 do not reflect real-life diagnostic sensitivities. Therefore, manufacturer-independent
38 quality checks of available AgPOCTs are needed, given the potential implications of
39 false-negative results.

40 **Objective:** The objective of this study was to develop a scalable approach for direct
41 comparison of the analytical sensitivities of commercially available SARS-CoV-2
42 antigen point-of-care tests (AgPOCTs) in order to rapidly identify poor performing
43 products.

44 **Methods:** We present a methodology for quick assessment of the sensitivity of
45 SARS-CoV-2 lateral flow test stripes suitable for quality evaluation of many different
46 products. We established reference samples with high, medium and low SARS-CoV-
47 2 viral loads along with a SARS-CoV-2 negative control sample. Test samples were
48 used to semi-quantitatively assess the analytical sensitivities of 32 different
49 commercial AgPOCTs in a head-to-head comparison.

50 **Results:** Among 32 SARS-CoV-2 AgPOCTs tested, we observe sensitivity
51 differences across a broad range of viral loads ($\sim 7.0 \cdot 10^8$ to $\sim 1.7 \cdot 10^5$ SARS-CoV-2
52 genome copies per ml). 23 AgPOCTs detected the Ct25 test sample ($\sim 1.4 \cdot 10^6$
53 copies/ ml), while only five tests detected the Ct28 test sample ($\sim 1.7 \cdot 10^5$ copies/
54 ml). In the low range of analytical sensitivity we found three saliva spit tests only
55 delivering positive results for the Ct21 sample ($\sim 2.2 \cdot 10^7$ copies/ ml). Comparison
56 with published data support our AgPOCT ranking. Importantly, we identified an
57 AgPOCT offered in many local drugstores and supermarkets, which did not reliably
58 recognize the sample with highest viral load (Ct16 test sample with $\sim 7.0 \cdot 10^8$ copies/
59 ml) leading to serious doubts in its usefulness in SARS-CoV-2 diagnostics.

60 **Conclusion:** The rapid sensitivity assessment procedure presented here provides
61 useful estimations on the analytical sensitivities of 32 AgPOCTs and identified a
62 widely-spread AgPOCT with concerning low sensitivity.

63

64

65 **Funding:** The study was supported by the Ministry of Science, Research and Arts of
66 the State of Baden-Wuerttemberg, Germany as well as internal funds from the
67 Heidelberg University Hospital. The corresponding authors had access to all data at
68 all time.

69

70 **Introduction**

71 In the SARS-CoV-2 pandemic, lateral flow antigen tests were developed as a rapid
72 alternative to SARS-CoV-2 reverse transcriptase quantitative polymerase chain
73 reaction (RT-qPCR)-based diagnostics. Because of their ease of use, lateral flow
74 antigen tests are applicable for point-of-care (POC) and self testing and can therefore
75 be incorporated in the daily life to support viral containment (WHO, Interim guidance,
76 2020). These tests, in the following referred to as antigen point-of-care tests
77 (AgPOCTs), are meanwhile widely used for SARS-CoV-2 diagnostic and screening
78 purposes. Currently, several hundred different SARS-CoV-2 AgPOCTs brands are
79 commercially available to meet the demand (545 products for professional use are
80 listed by the Federal Institute for Drugs and Medical Devices (Bundesinstitut für
81 Arzneimittel und Medizinprodukte (BfArM)); as of July 27, 2021). However,
82 sensitivity and specificity of the tests are not systematically assessed.

83 If a test is used by a professional operator, it falls under the 'low-risk' category of the
84 European Union directive on In Vitro Diagnostics (IVD), which currently governs
85 marketing authorization for IVDs in Europe. Under this directive, manufacturers can
86 still self-certify COVID-19 tests and waive independent verification of the tests before
87 they are marketed. The validation of the tests, which are offered online and in
88 pharmacies, is therefore not assured in the view of the Paul Ehrlich Institute (PEI),
89 Federal Institute for Vaccines and Biomedical Products, Germany
90 ([https://www.pei.de/DE/newsroom/hp-meldungen/2020/200323-covid-19-nat-
91 tests.html;jsessionid=F786872EBB85959AE8DA2B8FCB3ABE00.intranet222?nn=16
92 9730](https://www.pei.de/DE/newsroom/hp-meldungen/2020/200323-covid-19-nat-tests.html;jsessionid=F786872EBB85959AE8DA2B8FCB3ABE00.intranet222?nn=169730)). There is also evidence of counterfeiting here. A new legislation governing
93 independent validation by specialized and certified reference laboratories is planned,
94 but will only become effective in March 2022 at the earliest.

95 If a test is distributed for layperson use, it falls under a 'higher-risk' category and
96 requires independent validation. This validation of sensitivity is currently performed
97 by the PEI together with reference laboratories and a list with AgPOCTs passing their
98 criteria is provided (PEI, 2021). AgPOCTs failing the comparative evaluation by PEI
99 will be removed from the list provided by BfArM. This list, however, comprises only
100 products, which were also registered for listing by manufacturers or distributors
101 ([https://www.bfarm.de/DE/Medizinprodukte/Aufgaben/Spezialthemen/Antigentests/_n](https://www.bfarm.de/DE/Medizinprodukte/Aufgaben/Spezialthemen/Antigentests/_node.html)
102 [ode.html](https://www.bfarm.de/DE/Medizinprodukte/Aufgaben/Spezialthemen/Antigentests/_node.html)), rendering the absence of an AgPOCT from this list difficult to interpret.

103 Many in-depth AgPOCT characterization studies show that AgPOCT sensitivities can
104 vary substantially. One study reporting on the validation of 122 AgPOCs has recently
105 been published (Scheiblaue *et al.*, 2021). The authors found that 26 AgPOCTs do
106 not fulfill the required minimum sensitivity, clearly illustrating that quite a number of
107 circulating AgPOCT are insufficiently sensitive. In addition to this, significant brand-
108 to-brand and lot-to-lot variations were observed (Dinnes *et al.*, 2021). These
109 circumstances urge the need for an easy-to-use method to quickly assess AgPOCTs
110 at market entry and periodically thereafter for post-implementation quality control.

111 In this study, we sought to establish a procedure to rapidly evaluate a large number
112 of products for their sensitivity, using a small test sample panel and several tests per
113 product. For this we developed a strategy involving pooled samples and four different
114 dilution steps from high to low viral loads, and generated several hundred aliquots
115 thereof. Using this approach we then investigated 32 AgPOCTs, mainly tests
116 currently in use in the local area (Heidelberg, Germany). We compared the results
117 with data from the literature, which enabled us to draw conclusions on the validity of
118 our approach and the performance of the products investigated.

119 **Methods**

120 **Study design**

121 We tested the analytical sensitivity of a large number of commercially available
122 AgPOCTs by applying pooled samples from nasopharyngeal swabs with defined
123 SARS-CoV-2 viral loads including Ct16, Ct21, Ct25 and Ct28 ($\sim 7.0 \times 10^8$ to $\sim 1.7 \times 10^5$
124 genome copies per ml) as well as a pooled sample obtained from SARS-CoV-2
125 negative tested persons. Pools were generated using anonymized remnant swab
126 sample material that had been collected for clinical diagnosis of SARS-CoV-2
127 infection by RT-qPCR carried out by the Center for Infectious Diseases, Virology,
128 Heidelberg University Hospital, Germany. Pharyngeal swab specimens were
129 collected through the nose (nasopharyngeal) and contained in viral transport medium
130 (VTM). Per test, 50 μ l of the samples were mixed with the provided lysis buffer of
131 each AgPOCT and the tests were performed strictly according to the manufacturer's
132 instructions. After the recommended incubation time, images of the test chambers
133 were acquired using a Panasonic Lumix DMC-G70 camera equipped with a
134 Panasonic H-FS12060 objective. AgPOCTs were tested at least in duplicates with
135 the corresponding test samples. Test results were quantified by measuring the
136 background-corrected signal intensities of the test (T) band versus control (C) band
137 in ImageJ (v1.53c) using the "Gels" analysis function usually used for quantification
138 of Western Blot bands. For qualitative evaluation of the visibility of the test bands
139 (positive versus negative score), RGB pictures of AgPOCT results from randomly
140 chosen replicates were evaluated independently by three individuals in a blinded
141 manner. Furthermore, all additional replicates of all AgPOCTs and test samples were
142 scored independently by another person.

143 **Preparation of test samples from nasopharyngeal swabs**

144 Anonymized, remnant nasopharyngeal swab samples positively and negatively
145 tested for SARS-CoV-2 were obtained between May and July 2021 from the the
146 Center for Infectious Diseases, Virology, Heidelberg University Hospital, Germany.
147 Samples were stored in VTM. The Ct16, Ct21 and negative test samples were
148 prepared by pooling of 12-15 nasopharyngeal swab samples. Cell debris and other
149 solids were removed by centrifugation at 400g for 10min and subsequent transfer of
150 the supernatant into a new tube. Viral RNA was isolated from pools by manual lysis
151 and automated RNA extraction using the QIAamp Viral RNA Mini kit (Qiagen) on a
152 QIAcube Connect device (Qiagen). The cycle threshold (Ct) values of sample pools
153 were determined by RT-qPCR analysis using the LightMix® Modular Sarbecovirus
154 SARS-CoV-2 (TIB Molbiol) with the LightCycler® Multiplex RNA Virus Master
155 (Roche) and LightCycler480 II (Roche). Subsequently, pools were supplemented with
156 2 % TritonX-100 and c0mplete Ultra protease inhibitor (Roche) and if needed
157 adjusted with dilution buffer [2 mg/ ml BSA, 0.9 % NaCl, protease inhibitor]. Ct25 and
158 Ct28 test samples were prepared by dilution of the Ct21 test sample in the dilution
159 buffer. Samples were aliquoted (120 µl), immediately frozen on dry ice and stored at -
160 80°C. For AgPOCT testing, samples were freshly thawed on ice before use. Test
161 samples were validated using the SARS-CoV-2 Antigen Test by LumiraDx.

162 **AgPOCTs evaluated in this study**

163 We included a total of 32 AgPOCTs available at local supermarkets, pharmacies and
164 drugstores as well as on several online trade platforms (Table 1). Specific AgPOCTs
165 will be referred to as the respective manufacturer's name (in bold in Table 1). The
166 inspected AgPOCTs include both, tests for professional *in vitro* diagnostics use (#1-
167 14) as well as tests temporarily licensed for self-testing in Germany (#15-32) by the
168 Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und
169 Medizinprodukte (BfArM); Supplemental Figure S5). The majority of AgPOCTs
170 available were nasal or nasopharyngeal swab tests with the exception of BTNX,
171 Ritter, Joinstar, Realy (#11-14) among the tests for professional use and Sanicom,
172 Hygisun, fameditec (#30-32) among the self tests, which are all saliva spit tests, as
173 well as Watmind (#29), which is a saliva swab test.

174 For Lepu medical (#20 in Table 1), the AgPOCT with poorest results in our study, we
175 purchased different versions and additional batches for a more in-depth
176 characterization (Table 2).

Table 1: AgPOCTs investigated in this study. For each AgPOCT supplier, name, reference and LOT number are indicated. If tests obtained a temporary license for self-testing in Germany the corresponding BfArM GZ number is given as well. In addition, sample type and professional (pro) versus layman (lay) use is indicated. In the last column the type of distributor where AgPOCTs were purchased is noted.

#	Supplier	AgPOCT name	Specifications	Sample type	Use	Distributor
1	Abbott Rapid Diagnostics Jena GmbH	Panbio COVID-19 Ag Rapid test device (nasal)	REF: 41FK11 LOT: 41ADG244A	Nasal swab	pro	Online trade
2	Healgen Scientific Limited Liability Company	Coronavirus Ag Rapid Test Cassette (Swab)	REF: GCCOV-502a LOT: 2012650	Nasopharyngeal swab	pro	Online trade
3	RapiGEN , INC.	Biocredit COVID-19 Ag – One step Rapid Test	REF: G61RHA20 LOT: H073097SD	Nasopharyngeal swab	pro	Online trade
4	Beijing Beier Bioengineering Co., Ltd	COVID-19 Antigen Rapid Test Kit	REF: not specified LOT: 20210201	Nasopharyngeal swab	pro	Online trade
5	möLab GmbH	mö-screen Testkit Corona Antigen	REF: 0230005B1 LOS: 2104072	Nasal/ nasopharyngeal swab	pro	Online trade
6	Biomerica , Inc.	COVID-19 Antigen Rapid Test	REF: 1509A-25I LOT: COV6686	Nasopharyngeal swab	pro	Online trade
7	Joysbio (Tianjin) Biotechnology Co., Ltd	JOYSBIO SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold)	REF: G10313 LOT: 2021011607	Nasopharyngeal swab	pro	Online trade
8	Safecare Biotech (Hangzhou) Co., Ltd	COVID-19 Antigen Rapid Test Kit (Swab)	REF: COV Ag-6012 LOT: COV21040606	Nasopharyngeal swab	pro	Online trade

9	Hangzhou Testsea Biotechnology Co., Ltd	Testsealabs COVID-19 Antigen Test Cassette	REF: 2020013 vB/10 LOT: TL1C05	Nasal swab	pro	Online trade
10	ACON Biotech (Hangzhou) Co., Ltd	Flowflex SARS-Cov-2-Antigen-Schnelltest (Selbsttest)	REF: L031-11855 LOT: COV1030052	Nasal swab	pro	Online trade
11	BTNX Inc.	Rapid Response COVID-19 Antigen Rapid Test Cassette	REF: COV-2C25B LOT: COVG21030089	Saliva (spit)	pro	Online trade
12	Joysbio (Tianjin) Biotechnology Co., Ltd/ Ritter	Easy Check Spit test SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold)	REF: COV-AG-20/ G10313 LOT: 20210202	Saliva (spit)	pro	Online trade
13	Joinstar Biomedical Technology Co., Ltd.	COVID-19 Antigen Rapid Test (Latex)	REF: RPBH12360 LOT: COV2103002L	Saliva/ sputum (spit), stool	pro	Online trade
14	Hangzhou Realy Tech Co., Ltd	Novel Coronavirus (SARS-CoV-2) Antigen Rapid Test Device (Saliva)	REF: K590516D LOT: 202101022	Saliva (spit)	pro	Online trade
15	nal von minden GmbH	NADAL COVID-19 Ag Test	REF: 243103N-20H LOT: 175363 BfArM GZ: 5640-S-045/21	Nasal swab	lay	Online trade
16	SD Biosensor	SARS-CoV-2 Rapid Antigen Test	REF: 9901-NCOV-01G LOT: QCO390092I BfArM GZ: 5640-S-025/21	Nasal swab	lay	Online trade

17	Beijing Hotgen Biotech Co., Ltd	Coronavirus (2019-nCoV)-Antigentest	REF: 4260220532859 LOT: W2021032500/ W2021032602/ 1500 BfArM GZ: 5640-S-057/21	Nasal swab	lay	Supermarket Pharmacy
18	Guangzhou Wondfo Biotech Co., Ltd.	2019-nCoV Antigen Test (Lateral Flow Method)	REF: W634P0021 LOT: W634104116 BfArM GZ: 5640-S-179/21	Nasal swab	lay	Supermarket
19	Teda Laukoetter Technology GmbH	COVID-19 Antigen Schnelltest (kolloidales Gold) ANBIO Corona Antigen Nasentupfer	REF: A6061214 LOT: 2021046133/ 461310/036138 BfArM GZ: 5640-S-079/21	Nasal swab	lay	Drug store
20	Beijing Lepu medical Technology Co., Ltd	NASOCHECKcomofort SARS-CoV-2 Antigen-Schnelltest	REF: CG2701N LOT: 21CG2720X/ 18X BfArM GZ: 5640-S-104/21	Nasal swab	lay	Drug store
21	Hangzhou Clongene Biotech Co., Ltd	COVID-19 Antigen Rapid Test	REF 6950921302636 LOT: 2021030161 BfArM GZ: 5640-S-168/21	Nasal swab	lay	Online trade
22	Hangzhou Laihe Biotech Co., Ltd	LYHER Novel Coronavirus (COVID-19) Antigen Test Kit (Colloidal Gold) NASAL	REF: 303036 LOT: 2103049/47/ 89-01 BfArM GZ: 5640-S-009/21	Nasal swab	lay	Pharmacy
23	MP Biomedicals Germany GmbH	Rapid SARS-Cov-2 Antigen Test Card	REF: 07AG6001BS LOT: 21033003 BrArM GZ: 5640-S-076/21	Nasal swab	lay	Supermarket

24	Xiamen Boson Biotech Co., Ltd	Rapid SARS-CoV-2 Antigen Test Card	REF: 1N40C5-4 LOT: 21040609 BfArM GZ: 5640-S-007/21	Nasal swab	lay	Supermarket
25	NanoRepro AG	VIROMED for the detection of SARS-Cov-2 from anterior nasal swab	REF: B60500 LOT: 20210401B BrArM GZ: 5640-S-096/21	Nasal swab	lay	Drug store
26	Anhui Deepblue Medical Technology Co., Ltd	COVID-19 (SARS-CoV-2) Antigentestkit (kolloidales Gold)	REF: SL030101N-5 LOT: ST210405 BfArM GZ: 5640-S-086/21	Nasal swab	lay	Online trade
27	OFM GmbH	Deni COVID-19 Antigen Test – Selbsttest für Zuhause	REF: OFM-LSYBT-NS-1 LOT: P202103003 BfArM GZ: 5640-S-140/21	Nasal swab	lay	Drug store
28	Medice Arzneimittel Pütter GmbH & Co. KG	Medicovid-AG SARS-CoV-2 Antigen Selbsttest 5 NASE	REF: 1N40C5-4 LOT: 21041002 BfArM GZ: 5640-S-128/21	Nasal swab	lay	Online trade
29	Shenzhen Watmind Medical Co., Ltd	SARS-CoV-2 Antigen Schnelltest zur Eigenanwendung (kolloidales Gold)	REF: LFA0401-5N LOT: 21040904/ 21040704 BfArM GZ: 5640-032/21	Saliva (swab)	lay	Supermarket
30	MR Sanicom GmbH	COVID-19 Antigen Schnelltest zur Eigenanwendung (Speichel-/ Spucktest)	Barcode no: 4260729310002 LOT: CAG2104021G BfArM GZ: 5640-S-147/21	Saliva (spit)	lay	Drug store

31	Hygisun Anbio (Xiamen) Biotechnology Co., Ltd.	COVID-19 Antigen Schnelltest (kolloidales Gold)	REF: A6061213 LOT: 2021046132/ 2021036136/ 2021036137 BfArM GZ: 5640-S-058/21	Saliva (spit)	lay	Drug store
32	fameditec	CORA Check-19 Comfort	REF: K590516D/ LOT: 2021022019 BfArM GZ: 5640-S-154/21	Saliva (collected with sponge)	lay	Online trade

Table 2: Lepu medical AgPOCT products investigated in this study. AgPOCT products made by Beijing Lepu Medical Technology Co., Ltd. are referred to as Lepu medical AgPOCTs. Lepu medical AgPOCTs were purchased on different online trade platforms. For each Lepu medical AgPOCT, product name, packaging size and intended use (professional (pro) versus layman (lay) use), reference/ barcode number, LOT number as well as BfArM GZ number if applicable are indicated. Production and use-by date are noted in the last column.

Product name	Packaging size (use)	Specifications	Production and use-by date
SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold Immunochromatography) CE	Pack of 25 tests/ (pro)	Barcode: 6921807601020 LOT: 21CG2713X	Production date: 06/03/2021 Use-by date: 06/03/2022
		Barcode: same as above LOT: 21CG2715X	Production date: 03/11/2021 Use-by date: 03/11/2022
NASOCHECKcomfort SARS-CoV-2 Antigen Schnelltest Immunchromatographischer Test (kolloidales Gold). Schnell & angenehm! Einfache Anwendung im vorderen Nasenbereich.	Pack of 25 testes (lay)	REF: CG2725(N) Barcode: 4260716970042 LOT: 21CG2722X BfArM GZ: 5640-S-104/21	Production date: 31/03/202 Use-by date: 31/03/2022
NASOCHECKcomfort SARS-CoV-2 Antigen-Schnelltest. Zur Eigenanwendung. Schnell & angenehm! Einfache Anwendung im vorderen Nasenbereich.	Single pack (narrow) (lay)	REF: CG2701N Barcode: 4260716970059 LOT: 21CG2727X BfArM GZ: 5640-S-104/21	Production date: 11/04/2021 Use-by date: 11/04/2022
NASOCHECKcomfort SARS-CoV-2 Antigen-Schnelltest. Zur Eigenanwendung. Schnell & angenehm! Einfache Anwendung im vorderen Nasenbereich.	Single pack (thick) (lay)	REF: CG2701N Barcode: 4260716970059 LOT: 21CG2720X BfArM GZ: 5640-S-104/21	Production date: 26/03/2021 Use-by date: 26/03/2022
		REF, barcode, BfArM GZ: same as above LOT: 21CG2724X	Production date: 04/04/2021 Use-by date: 04/04/2022

177 **Results**

178 **Generation of test samples for standardized AgPOCT evaluation**

179 In the present study, we sought to establish a standardized procedure to rapidly
180 assess the sensitivities of a large number of SARS-COV-2 AgPOCTs. To this end,
181 we generated a collection of test samples from pooled nasopharyngeal swabs from
182 SARS-CoV-2 positive tested and negative tested individuals. Ct values of the SARS-
183 CoV-2 positive pools were determined by RT-qPCR and test samples were prepared
184 accordingly. The test sample collection comprised four SARS-CoV-2 positive pools
185 with defined viral loads (Ct16, Ct21, Ct25, Ct28) and one SARS-CoV-2 negative pool.
186 Per test sample, >200 aliquots with 120 µl sample volume each were prepared,
187 allowing a quick and standardized evaluation of the analytical sensitivities of a large
188 number of different AgPOCTs.

189 We estimated that our test sample collection covers a range from $\sim 7.0 \times 10^8$ (Ct=16) to
190 $\sim 1.7 \times 10^5$ (Ct=28) SARS-CoV-2 genome copies per ml (Supplemental Table S6). We
191 qualitatively validated our test sample collection using the LumiraDx SARS-CoV-2 Ag
192 Test device, which was shown to have a high analytical sensitivity (Krüger *et al.*,
193 2021). We used 50 µl of a test sample, each for the LumiraDx analysis and for all
194 AgPOCTs evaluated in this study, as described before (Corman *et al.*, 2021;
195 Puyskens *et al.*, 2021). All four SARS-CoV-2 positive test samples tested positive for
196 SARS-CoV-2, while the negative test sample was recognized as negative in the
197 LumiraDx analysis.

198 **Quantitative and qualitative assessment of AgPOCT analytical sensitivity**

199 We tested a total of 32 AgPOCTs (Table 1). 12 AgPOCTs were purchased from local
200 resellers (pharmacies, drugstores, supermarkets). Another 20 tests were purchased
201 online. We performed the tests over 10 days, with the help of four students, during
202 the course of four weeks. Freshly thawed aliquots of the Ct21, Ct25, and Ct28 test
203 samples as well as the negative sample were used. We conducted two to four
204 replicates per product, and acquired images of each of the tests at the time points
205 specified by the manufacturers. The Ct16 test sample was only used for AgPOCTs
206 that had low performance with the Ct21 test sample. For quantitative evaluation,
207 signal intensities of the test (T) and the control (C) bands were measured and the
208 ratio of these values (T/C ratio) was determined (Figure 1A). In addition, we scored a
209 binary (positive or negative) test result using visual inspection of the images by four
210 different persons (Figure 1B).

211 For 31 of 32 investigated AgPOCTs, an average $T/C_{Ct25} > 0$ was determined for all
212 virus-containing samples and not for the negative control sample (Figure 1A). This
213 indicates that the digital quantification detects test band signals for 31 AgPOCTs
214 using the Ct25 test sample, albeit sometimes with extremely weak signal intensities.
215 Only for Jointstar, one replicate of the negative test sample resulted in a false
216 positive test band indicated by a $T/C_{Neg.} > 0$. In contrast to the more sensitive digital
217 quantification, visual inspection did only score a positive result for 28 of 31 AgPOCTs
218 with a $T/C_{Ct25} > 0$ (Figure 1B). This also holds true for the visual assessment of the
219 results of technical replicates, e.g. for Jointstar, the negative sample with a $T/C_{Neg.} > 0$
220 scored negative in the visual inspection. We could not establish a specific T/C value
221 threshold to explain the results of the visual assessment, indicating that these ratios
222 are product-specific. This can be explained by different dyes and dye-systems, and

223 by the fact that the visual assessment was conducted using color vision, while for T/C
224 quantification grayscale images were used. We also observed a large coefficient of
225 variation (CV) for some of the tests, in particular for samples with very small T/C
226 ratios, emphasizing weak signals close to the detection limit of the digital
227 quantification (Supplemental Figure S1C).

228 We grouped the tested AgPOCTs into categories with low (Group III), medium
229 (Group II) and high (Group I) sensitivity based on the reliability to detect a given
230 SARS-CoV-2 positive sample. A sample was considered reliably detected by a given
231 AgPOCT when all or the majority of replicates (at least two out of three or three out of
232 four replicates) of a given sample were scored positive. If none or the minority of
233 replicates of a given sample was detected by the corresponding AgPOCT, reliability
234 requirements were not met.

235 One exception was Lepu medical (Table 1, AgPOCT #20; Table 2, last row) which
236 did not fulfill the requirements for any of these groups. For Group III AgPOCTs with
237 the lowest sensitivity, the minimum criterion was that the tests were able to reliably
238 detect the Ct21 sample, and the Lepu medical tests failed this, as they did not even
239 reliably score positive with the Ct16 sample ($\sim 7.0 \cdot 10^8$ copies/ ml; Figure 1B). To
240 investigate this product further we used individual unprocessed nasal/
241 nasopharyngeal swab samples with low Ct values (Ct13.3 to Ct18.4) on this and
242 another poor performing product. Comparison of these results to the Ct16 test
243 sample confirmed the low sensitivity of the Lepu medical (Supplemental Figure S2).
244 Only for samples with very low Ct values (Ct \sim 13) T/C ratios were obtained that can
245 be detected easily visually (Supplemental Figure S2A). This suggests that this
246 product is not completely non-functional, but largely insensitive. Since Lepu medical
247 AgPOCTs have been widely used in Germany and other European countries we

248 retrieved several Lepu medical products available on different online trade platforms
249 (Table 2). These included two different batches of a Lepu medical product intended
250 for professional use (Table 2, first row, no BfArM GZ number, CE mark). Additionally,
251 we included different batches and deviations of the Lepu medical AgPOCT described
252 before (Table 1, AgPOCT #20; Table 2, last three rows). These products were
253 provided with the same BfArM GZ number (5640-S-104/21), which cannot be found
254 on the BfArM list anymore (Supplemental Figure S5). We investigated their
255 performance in direct comparison in multiple replicates using Ct16, Ct21 and Ct25
256 test samples (Supplemental Figure S3). This revealed high variation of the
257 determined T/C ratios, with coefficients of variation (CV) ranging from 0.26 to 1.54
258 and a median CV of 0.50 (Supplemental Figure S4C). In contrast, the median CV of
259 the other 31 investigated AgPOCTs with Ct16-25 test samples was 0.11
260 (Supplemental Figure S1C). This indicates a larger variability of the test results not
261 only for different implementations of the Lepu medical AgPOCTs, but also for
262 different batches of the same Lepu medical product, compared to all other AgPOCTs
263 investigated in this study.

264 AgPOCTs in Group III only reliably detected the Ct21 sample ($\sim 2.2 \cdot 10^7$ copies/ ml)
265 and include Hygisun, Joinstar and Ritter. Of note is that all of them are saliva based
266 spit tests (Table 1), which are provided with a considerably larger amount of lysis
267 buffer (500-1000 μ l lysis buffer; Figure 1C) than most other AgPOCTs resulting in an
268 increased dilution of the test sample compared to AgPOCTs for nasal samples,
269 which are provided on average with 320 μ l lysis buffer (Figure 1C). The resulting
270 higher dilution of the sample together with the possibility of lower virus concentration
271 in saliva versus nasal or nasopharyngeal swabs may further influence the sensitivity
272 of these saliva tests.

273 The large majority of the investigated AgPOCTs (23 out of 32) delivered visible
274 positive results with the Ct25 sample ($\sim 1.4 \cdot 10^6$ copies/ ml, Group II). Among these
275 23 AgPOCTs, positive scoring was fully reproducible in all replicates for 17
276 AgPOCTs. AgPOCTs intended for professional use (sorted ascending according to
277 T/C_{Ct25} : Safecare, Realy, Healgen, ACON, Beier, Testsea, BTNX and Biomerica)
278 largely cluster in the upper half of the T/C_{Ct25} ranking, while tests licensed for self-
279 testing largely cluster in the lower half (sorted ascending according to T/C_{Ct25} :
280 Sanicom, fameditec, OFM, Deepblue, NanoRepro, nal von minden, Teda, Laihe and
281 Boson). Interestingly, among both tests for professional and for layman use, saliva
282 spit tests (Realy, Sanicom, fameditec) appear largely inferior compared to nasal
283 swab tests in this setting with the exception of BTNX, which is the sixth highest
284 ranked AgPOCT among all investigated tests. Six AgPOCTs in Group II (sorted
285 ascending according to T/C_{Ct25} : Joysbio, RapiGEN, Hotgen, SD Biosensor, Abbott
286 and Wondfo) failed in one out of three to four replicates to detect the Ct25 sample,
287 which is represented by larger CV values ranging from 0.26 to 0.87 (Supplemental
288 Figure S1C).

289 Using the Ct28 test sample ($\sim 1.7 \cdot 10^5$ copies/ ml), 14 out of 32 AgPOCTs yielded a
290 $T/C_{Ct28} > 0$, however, only five reliably scored positive in the visual investigation
291 (Group I). These include (sorted in ascending order according to T/C_{Ct25}) möLab,
292 Medice, MP, Clongene and Watmind, three of which are temporarily licensed for self-
293 testing (Table 1, Supplemental Figure S5). All, except möLab delivered a positive
294 visual result in all three replicates.

295 Taken together, the data presented here demonstrate that the different SARS-CoV-2
296 AgPOCTs available deviate largely in the analytical sensitivity of the lateral flow test
297 stripes and provided buffer systems, corresponding more than two orders of
298 magnitude of viral genome copies per ml ($7.0 \cdot 10^8$ to $1.7 \cdot 10^5$). Additionally, we

299 revealed a great variability in results delivered with different Lepu medical AgPOCT
300 versions and batches emphasizing the need for regular quality monitoring.

301 **Discussion**

302 We developed a straight-forward strategy to evaluate the technical sensitivity of
303 AgPOCTs for SARS-CoV-2. Using a set of four SARS-CoV-2 positive reference
304 samples spanning the relevant dynamic range of the typical sensitivity of AgPOCTs
305 ($\sim 1.7 \cdot 10^5$ to $\sim 2.2 \cdot 10^7$ SARS-CoV-2 genome copies per ml) we were able to group 32
306 commercially available products into AgPOCT groups with high, average and low
307 sensitivity (Group I-III). Most importantly, we identified one product that did not detect
308 any of the test samples and therefore is considered not suitable for SARS-CoV-2
309 diagnostics.

310 The majority of tests investigated in this study reliably detected the Ct25 test sample
311 as SARS-CoV-2 positive (Group II). Some of these AgPOCTs have been thoroughly
312 characterized, including Abbott, RapiGEN, Healgen, nal von minden and SD
313 Biosensor by Corman and colleagues (Corman *et al.*, 2021) among others (Strömer
314 *et al.*, 2021; Stokes *et al.*, 2021; Merino *et al.*, 2021; Schildgen *et al.*, 2021;
315 Seynaeve *et al.*, 2021; Nordgren *et al.*; Puyskens *et al.*, 2021; Scheiblauer *et al.*,
316 2021; Kohmer *et al.*, 2021; Wagenhäuser *et al.*, 2021; Berger *et al.*, 2021;
317 Jegerlehner *et al.*, 2021; Iglò *et al.*, 2021; Bekliz *et al.*, 2021; Cubas-Atienzar *et al.*,
318 2021, Haage *et al.*, 2021 and more). Corman and colleagues determined 95% limits
319 of detection for each AgPOCT using 138 SARS-CoV-2 positive clinical samples with
320 viral loads ranging from $1.9 \cdot 10^4$ to $2.8 \cdot 10^9$ genome copies per ml. Among the
321 AgPOCTs also tested in this study, Healgen was found to be most sensitive closely
322 followed by Abbott, SD Biosensor and nal von minden - all with a 95% limit of
323 detection between $2.3 - 9.3 \cdot 10^6$ SARS-COV-2 genomes per swab. In contrast, for

324 RapiGEN a 95% limit of detection more than three orders of magnitudes lower was
325 found. This discrepancy in performance between RapiGEN and the above mentioned
326 products is supported by other studies (Brümmer *et al.*, 2021). In our analysis, this
327 trend is also reflected even though we cannot resolve the limits of detection in such
328 great detail: For Healgen and nal von minden, detection of the Ct25 test sample
329 ($\sim 1.4 \cdot 10^6$ copies/ ml) was robust with all replicates being positively scored. For
330 RapiGEN, Ct25 test sample detection was less reliable and based on the T/C_{Ct25} , this
331 product is ranked in the lowest quarter among all AgPOCTs investigated.

332 Among the 32 investigated AgPOCTs, we identified four reliably well performing
333 AgPOCTs, which detected the Ct28 test sample ($\sim 1.7 \cdot 10^5$ copies/ ml) as SARS-
334 CoV-2 positive in all replicates (Group I). These include in ascending order (based on
335 T/C_{Ct25}) Medice, MP, Clongene and Watmind. The latter represents the test winner in
336 our study and is also among the best three AgPOCTs out of 122 tested products with
337 a sensitivity of 82 % in samples with Ct values ranging from 17 to 35 corresponding
338 to viral loads of $>10^8$ to 10^3 SARS-CoV-2 genome copies per ml (Scheiblauer *et al.*,
339 2021).

340 Group III includes AgPOCTs with low performance as these only detected the Ct21
341 test sample as SARS-CoV-2 positive. For Joinstar, using Latex beads for
342 visualisation, evidence provided by Scheiblauer and colleagues (2021) suggests that
343 this test is non-functional with 0% sensitivity for all sample panels supporting the low
344 ranking of Joinstar in this study. In our analysis we detected very weak bands for the
345 Ct21 and Ct16 test samples, however, these were considerably weaker than for all
346 other tests suggesting the possibility that latex beads used for visualisation do fail to
347 produce a strong signal. Besides Joinstar, Ritter and Hygisun, both saliva spit tests
348 similar to Joinstar, also showed low sensitivity in our studies. While we could not find

349 independent evaluation studies for these products, both can be found on the BfArM
350 list (as of July 23, 2021; Supplemental Figure S5).

351 Among the low ranked AgPOCTs, the sensitivity of Lepu medical AgPOCT was
352 exceptionally low as this test failed to deliver a visible positive test result in most
353 replicates, even for the Ct16 sample. In addition to its poor performance in SARS-
354 CoV-2 diagnostics, out of 20 performed Lepu medical tests three tests technically
355 failed, indicated by the absence of the control band. Importantly, this last test is a
356 very popular product in the area where this study was conducted, available at many
357 drugstores and supermarket chains. Of note is also that Lepu medical differs from
358 other AgPOCTs in its design and sample application. Technical failure did not occur
359 in any of the other AgPOCTs, in which the immunochromatography paper is
360 embedded in the common plastic cassettes. In other studies tested Lepu medical
361 AgPOCT products performed better (Scheiblauer *et al.*, 2021; Baro *et al.*, 2021), e.g.
362 in the setting of Scheiblauer *et al.* (2021), a sensitivity of 100 % was found for a Lepu
363 medical AgPOCT and test panel members with Ct values ranging from Ct17 to Ct25.
364 As the AgPOCTs used in these studies are not specified with reference/product and
365 LOT number, it is possible that a different Lepu medical product or batch was used.
366 We purchased different Lepu medical AgPOCT products available online and
367 compared performances on the pooled test samples as well as on raw, unprocessed
368 swab samples (Supplemental Figure 3). We tested two batches of a CE-marked
369 product and four Lepu medical with the same BfArM GZ number, but different
370 packaging sizes (Table 2). Indeed, we identified two Lepu medical products
371 performing better than shown in Figure 1, however, these performances were not
372 reproducible with other batches of the same product (Supplemental Figure 3)
373 indicating batch-specific variation of the quality. This again emphasizes the
374 importance of a simple method to assay the performance of a product and

375 corresponding batches. Taken together, comparison with published data for some of
376 the investigated products confirmed our results. Therefore, we provide evidence that
377 our chosen strategy constitutes a viable solution to rapidly assess the sensitivity of
378 SARS-CoV-2 AgPOCTs.

379 It is important to mention that the sensitivity of an AgPOCT is the product of multiple
380 factors; the sensitivity of the test stripe and buffer system used are important
381 contributing factors, but not the only ones. Another is the volume of the lysis buffer
382 provided with each AgPOCT. The volume varies between tests of different
383 manufacturers resulting in a 2.6- to 20-fold dilution of the test samples during the
384 procedure (Figure 1C). In this study, test results were not corrected for these different
385 dilution factors, because the sample dilution is an internal property of each AgPOCT.
386 By using the same sample volume for each AgPOCT we also neglect potential
387 differences in swab properties, such as absorption volume or sample specimen
388 (saliva, nasal or nasopharyngeal samples), which affect the diagnostic sensitivity of
389 AgPOCTs. However, we note that for tests based on nasal swabs the used volume of
390 50 μ l approximates the quantity absorbed by these swabs (Corman *et al.*, 2021).
391 Furthermore, the AgPOCT-specific instructions for self-sampling, which will influence
392 how careful a sample is collected, can also influence the diagnostic sensitivity of a
393 test. In light of these considerations we want to emphasize that this evaluation
394 method only and exclusively focuses on comparing the technical sensitivity of the
395 lateral flow test strips from different test manufacturers, in combination with the
396 provided lysis buffers.

397 Currently, there are more than 500 different products available for SARS-CoV-2
398 diagnostics, many of which lack independent assessment of their performance. In
399 most cases the clinical sensitivity values provided by the manufacturer (e.g. in Figure

400 1C) are far >90% (Figure 1C). However, detailed information on specimen collection
401 and viral loads are usually not provided rendering these values largely inconclusive
402 and misleading for laymen. Considering that individual products use different
403 antibodies in varying amounts with different specificities and affinities sometimes
404 recognizing different proteins in the viral particle with differing abundances, and
405 diverse staining methods, these conspicuously similar values for clinical sensitivity
406 given by the manufacturer are also unlikely. Therefore, an independent, rapid and
407 critical evaluation of AgPOCTs available is required in order to determine the realistic
408 performance of AgPOCT relevant to the daily user and especially to identify poor
409 performing products. Given the huge number of products available for rapid SARS-
410 CoV-2 diagnostics, in-depth studies evaluating the quality of AgPOCTs in a time-
411 intensive procedure will not be available any time soon for all products available.
412 Therefore, the procedure presented here involving a reduced test sample collection
413 and minimal labor represents a feasible strategy for prompt evaluation of available
414 AgPOCTs for their usability in SARS-CoV-2 diagnostics. We provide a useful
415 estimation of the limits of detection for the investigated AgPOCTs as the dimensions
416 and trends are comparable to results from much more laborious in-depth studies.
417 Importantly, using this approach we revealed very heterogeneous results for the
418 Lepu medical AgPOCT, which precludes in our opinion the use of this product (or
419 product family) for SARS-CoV-2 diagnostics. In conclusion, we suggest this
420 procedure as a rapid alternative to investigate Covid-19 AgPOCs in the absence of
421 reliable data that validate the performance of a specific product and related batches.

	A Means of T/C ratios					B Pos. scores/ replicates					C Additional information			
	Ct16	Ct21	Ct25	Ct28	Neg.	Ct16	Ct21	Ct25	Ct28	Neg.	Sample type	Stated sensitivity [%]	Lysis buffer [µl]	Dil. factor
Watmind	n.d.	1,81	0,51	0,08	0,00	n.d.	3/3	4/4	3/3	0/2	sal	90,45	300	6
Clongene	n.d.	1,38	0,48	0,10	0,00	n.d.	3/3	4/4	4/4	0/3	nas	91,4	300	6
MP	n.d.	1,08	0,28	0,04	0,00	n.d.	3/3	3/3	3/3	0/2	nas	96,19	250	5
Boson	n.d.	1,05	0,22	0,02	0,00	n.d.	3/3	5/5	1/2	0/2	nas	96,19	200	4
Biomerica	n.d.	0,78	0,22	0,06	0,00	n.d.	3/3	3/3	1/3	0/3	np	94,7	300	6
BTNX	n.d.	1,04	0,21	0,01	0,00	n.d.	3/3	3/3	0/3	0/3	sal	90,6	300	6
Medice	n.d.	0,92	0,20	0,03	0,00	n.d.	2/2	2/2	2/2	0/2	nas	96,19	250	5
Testsea	n.d.	0,79	0,16	0,01	0,00	n.d.	3/3	3/3	0/3	0/3	nas	97,6	300	6
Beier	n.d.	1,75	0,15	0,00	0,00	n.d.	2/2	2/2	0/2	0/2	np	96,5	450	9
Laihe	n.d.	1,03	0,15	0,01	0,00	n.d.	3/3	4/4	1/3	0/2	nas	95	300	6
ACON	n.d.	0,94	0,15	0,02	0,00	n.d.	3/3	3/3	1/3	0/3	nas	97,1	350	7
Healgen	n.d.	0,93	0,13	0,01	0,00	n.d.	4/4	4/4	1/3	0/4	np	96,72	300	6
möLab	n.d.	0,76	0,12	0,02	0,00	n.d.	2/2	3/3	2/3	0/2	nas/np	97,25	300	6
Teda	n.d.	0,87	0,12	0,00	0,00	n.d.	4/4	4/4	0/3	0/4	nas	93,87	350	7
Wondfo	n.d.	0,98	0,11	0,00	0,00	n.d.	2/2	2/3	0/2	0/2	nas	97,83	400	8
Abbott	n.d.	1,20	0,09	0,00	0,00	n.d.	4/4	3/4	0/3	0/4	nas	98,1	300	6
nal von minden	0,48	0,50	0,09	0,01	0,00	2/2	4/4	4/4	0/3	0/4	nas	94,1	350	7
Realy	n.d.	0,89	0,09	0,01	0,00	n.d.	2/2	3/3	0/3	0/2	sal	92,9	130	2,6
NanoRepro	0,77	0,56	0,08	0,00	0,00	2/2	3/3	3/3	0/3	0/2	nas	97,33	500	10
SD Biosensor	n.d.	1,12	0,07	0,00	0,00	n.d.	4/4	3/4	0/3	0/4	nas	83,3	300	6
Deepblue	n.d.	0,67	0,07	0,00	0,00	n.d.	2/2	3/3	0/3	0/2	nas	96,4	300	6
OFM	n.d.	0,92	0,07	0,00	0,00	n.d.	3/3	3/3	0/3	0/2	nas	96,8	400	8
Hotgen	n.d.	0,68	0,06	0,00	0,00	n.d.	3/3	3/4	0/3	0/3	nas	95,37	300	6
fameditec	n.d.	0,51	0,06	0,00	0,00	n.d.	3/3	3/3	0/2	0/2	sal	96,3	250	5
Sanicom	1,10	0,63	0,06	0,00	0,00	2/2	3/3	3/3	0/3	0/2	sal	96,1	1000	20
RapiGEN	n.d.	0,99	0,05	0,00	0,00	n.d.	3/3	2/3	0/3	0/3	np	90,2	350	7
Safecare	0,52	0,43	0,05	0,00	0,00	3/3	3/3	3/3	0/3	0/3	np	97,04	350	7
Joysbio	0,30	0,31	0,03	0,00	0,00	2/2	3/3	2/3	0/3	0/3	np	98,13	350	7
Ritter	n.d.	0,16	0,02	0,00	0,00	n.d.	2/2	0/3	0/3	0/2	sal	95,1	500	10
Joinstar	0,10	0,09	0,02	0,00	0,01	2/2	3/3	1/3	0/3	0/3	div	92,2	1000	20
Hygisun	n.d.	0,36	0,01	0,00	0,00	n.d.	3/3	1/3	0/3	0/3	sal	98,94	1000	20
Lepu medical	0,07	0,00	0,00	n.d.	0,00	3/7	1/8	0/1	n.d.	0/2	nas	95,06	150	3

Figure 1: Quantitative and qualitative evaluation of 32 SARS-CoV-2 AgPOCTs in a rapid sensitivity assessment approach. (A) Investigated AgPOCT are listed with the means of T/C ratios (test band (T) intensity to control (C) band intensity) for each Ct test sample. T/C ratios are color-coded in shades of red (highest values with most intense red). Blue color highlights zeros indicating the absence of measurable signal at the test band position. Ct16 test sample was only used on AgPOCTs with exceptionally low performance in

detection of the Ct21 sample. AgPOCTs are ranked according to their T/C_{Ct25} ratio. (B) Scoring results of visual inspection for all replicates. Full reproducibility of positive scores in all replicates is highlighted in green, positive scores in the majority of replicates in yellow, positive scores in the minority of replicates in orange and no positive scores in any replicate in light red. n.d. = not determined (grey). Double line indicates the limit of reliable detection of SARS-CoV-2 positive samples (reliability defined by reproducibility of positive scores in all (green) or most (yellow) replicates of a given Ct test sample). (C) Additional information on investigated AgPOCTs: Sample type (nasal (nas)/ nasopharyngeal (np) swab, saliva (sal) or diverse (div)), sensitivities of AgPOCTs according to the corresponding manufacturer's package insert, volumes of provided lysis buffer and the resulting dilution factor for the Ct test samples ($V = 50 \mu\text{l}$) are given.




Figure 2: Representative images of SARS-CoV-2 AgPOCTs lateral flow test stripes treated with corresponding Ct test samples. Contrast settings were optimized for each AgPOCT example image set in order to ensure best visibility of the test bands. AgPOCT example images are arranged (from top left to bottom right) according to the ranking presented in Figure 1. Red line indicates the limit of reliable detection (see Figure 1A, B). Arrowheads highlight positions of control (C) and test (T) band.

422 References

- 423 **Baro** B., Rodo P., Ouchi D., Bordoy A. E., Saya Amaro E. N., Salsench S. V.,
424 Molinos S., Alemany A., Urbals M., Corbacho-Monné M., Millat-Martinez P., Marks
425 M., Clotet B., Prat N., Ara J., Vall-Mayans M., G-Beiras C., Bassat Q., Blanco I., Mitjà
426 O. (2021). Performance characteristics of five antigen-detecting rapid diagnostic test
427 (Ag-RDT) for SARS-CoV-2 asymptomatic infection: a head-to-head benchmark
428 comparison. MedRxiv, 2021.02.11.21251553. Retrieved from
429 <https://doi.org/10.1101/2021.02.11.21251553>
- 430 **Bekliz**, M., Adea, K., Essaidi-Laziosi, M., Sacks, J. A., Escadafal, C., Kaiser, L., &
431 Eckerle, I. (2021). Analytical comparison of nine SARS-CoV-2 antigen-detecting
432 rapid diagnostic tests for emerging SARS-CoV-2 variants. MedRxiv, 114(June),
433 e00146. Retrieved from <https://doi.org/10.1016/j.sciaf.2019.e00146>
- 434 **Berger**, A., Nsoga, M. T. N., Perez-Rodriguez, F. J., Aad, Y. A., Sattonnet-Roche, P.,
435 Gayet-Ageron, A., ... Eckerle, I. (2021). Diagnostic accuracy of two commercial
436 SARSCoV- 2 antigen-detecting rapid tests at the point of care in community-based
437 testing centers. PLoS ONE, 16(3 March 2021), 1–12.
438 <https://doi.org/10.1371/journal.pone.0248921>
- 439 **Brümmer**, L. E., Katzenschlager, S., Gaeddert, M., Erdmann, C., Schmitz, S., Bota,
440 M., ... Denkinger, C. M. (2021). The accuracy of novel antigen rapid diagnostics for
441 SARS-CoV-2: a living systematic review and meta-analysis. MedRxiv,
442 2021.02.26.21252546. Retrieved from <https://doi.org/10.1101/2021.02.26.21252546>
- 443 **Corman**, V. M., Haage, V. C., Bleicker, T., Schmidt, M. L., Mühlemann, B.,
444 Zuchowski, M., ... Drosten, C. (2021). Comparison of seven commercial SARS-CoV-
445 2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study. The
446 Lancet Microbe, 5247(21), 1–9. [https://doi.org/10.1016/S2666-5247\(21\)00056-2](https://doi.org/10.1016/S2666-5247(21)00056-2)
- 447 **Cubas-Atienzar**, A. I., Kontogianni, K., Edwards, T., Buist, K., Thompson, C. R.,
448 Williams, C. T., ... Adams, R. (2021). Limit of detection in different matrices of
449 nineteen commercially available rapid antigen tests for the detection of SARS-CoV-2
450 Liverpool School of Tropical Medicine , Centre for Drugs and Diagnostics , Liverpool ,
451 L3 5QA , UK Liverpool School of Tropical. Retrieved from
452 <https://www.medrxiv.org/content/10.1101/2021.03.19.21253950v1.full.pdf>
- 453 **Dinnes**, J., Deeks, J. J., Adriano, A., Berhane, S., Davenport, C., Dittrich, S., ... Van
454 den Bruel, A. (2020). Rapid, point-of-care antigen and molecular-based tests for
455 diagnosis of SARS-CoV-2 infection. Cochrane Database of Systematic Reviews,
456 2020(8). <https://doi.org/10.1002/14651858.CD013705>
- 457 **Federal Institute for Drugs and Medical Devices** (Bundesinstitut für Arzneimittel
458 und Medizinprodukte (BfArM)). Antigen-Tests zum direkten Erregernachweis des
459 Coronavirus.
460 <https://antigentest.bfarm.de/ords/f?p=110:100:16622641307467::: &tz=2:00>
- 461 **Igliò**, Z., Velzing, J., Van Beek, J., Van de Vijver, D., Aron, G., Ensing, R., ...
462 Molenkamp, R. (2021). Clinical evaluation of roche sd biosensor rapid antigen test for

- 463 sars-cov-2 in municipal health service testing site, the netherlands. *Emerging*
464 *Infectious Diseases*, 27(5), 1323–1329. <https://doi.org/10.3201/eid2705.204688>
- 465 **Jegerlehner**, S., Suter-riniker, F., Jent, P., Bittel, P., & Nagler, M. (2021). Diagnostic
466 accuracy of a SARS-CoV-2 rapid antigen test in real-life clinical settings. *International*
467 *Journal of Infectious Diseases*, 109, 118–122.
468 <https://doi.org/10.1016/j.ijid.2021.07.010>
- 469 **Kohmer**, N., Toptan, T., Pallas, C., Karaca, O., Pfeiffer, A., Westhaus, S., ...
470 Rabenau, H. F. (2021). The Comparative Clinical Performance of Four SARS-CoV-2
471 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro. *Journal of Clinical*
472 *Medicine*, 10(2), 328. <https://doi.org/10.3390/jcm10020328>
- 473 **Krüger**, L. J., Klein, J. A. F., Tobian, F., Gaeddert, M., Lainati, F., Klemm, S., ...
474 Jones, T. C. (2021). Evaluation of accuracy, exclusivity, limit-of-detection and ease-
475 of-use of LumiraDx™ Antigen-detecting point-of-care device for SARS-CoV-2.
476 *MedRxiv*, 1–37.
- 477 **Merino**, P., Guinea, J., Munoz-Gallego, I., González-Donapetry, P., Galán, J. C.,
478 Antona, N., ... Group, the S. P. T. C.-19 validation. (2021). Multicenter evaluation of
479 the Panbio™ COVID-19 rapid antigen- detection test for the diagnosis of SARS-
480 CoV-2 infection. *Clinical Microbiology and Infection*, 27(January), 758–761.
- 481 **Nordgren**, J., Sharma, S., Olsson, H., Jämtberg, M., Falkeborn, T., Svensson, L., &
482 Hagbom, M. (2021). SARS-CoV-2 rapid antigen test : High sensitivity to detect
483 infectious virus. *Journal of Clinical Virology*, 140(January).
- 484 **Paul Ehrlich Institute** (PEI), Federal Institute for Vaccines and Biomedicines (12
485 July, 2021). Vergleichende Evaluierung der Sensitivität von SARS-CoV-2
486 Antigenschnelltests.
487 [https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/evaluierung-](https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/evaluierung-sensitivitaet-sars-cov-2-antigentests-04-12-2020.pdf?__blob=publicationFile&v=48)
488 [sensitivitaet-sars-cov-2-antigentests-04-12-2020.pdf?__blob=publicationFile&v=48](https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/evaluierung-sensitivitaet-sars-cov-2-antigentests-04-12-2020.pdf?__blob=publicationFile&v=48)
- 489 **Puyskens**, A., Krause, E., Michel, J., Nübling, M., Scheiblaue, H., Bourquain, D., ...
490 Nitsche, A. (2021). Establishment of an evaluation panel for the decentralized
491 technical evaluation of the sensitivity of 31 rapid detection tests for SARS-CoV-2
492 diagnostics. *MedRxiv*.
- 493 **Scheiblaue**, H., Filomena, A., Nitsche, A., Puyskens, A., Corman, V. M., Drosten,
494 C., ... Nübling, C. M. (2021). Comparative sensitivity evaluation for 122 CE-marked
495 SARS-CoV-2 antigen rapid tests. *MedRxiv*, 2021.05.11.21257016. Retrieved from
496 <http://medrxiv.org/content/early/2021/05/12/2021.05.11.21257016.abstract>
- 497 **Schildgen**, V., Demuth, S., Lüsebrink, J., & Schildgen, O. (2021). Limits and
498 opportunities of sars-cov-2 antigen rapid tests: An experienced-based perspective.
499 *Pathogens*, 10(1), 1–7. <https://doi.org/10.3390/pathogens10010038>
- 500 **Seynaeve**, Y., Heylen, J., Fontaine, C., Maclot, F., Meex, C., Diep, A. N., ... Descy,
501 J. (2021). Evaluation of Two Rapid Antigenic Tests for the Detection of SARS-CoV-2
502 in Nasopharyngeal Swabs. *Journal of Clinical Medicine*, (M), 1–9.

- 503 **Stokes**, W., Berenger, B. M., Portnoy, D., Scott, B., Szelewicki, J., Singh, T., ...
504 Tipples, G. (2021). Clinical performance of the Abbott Panbio with nasopharyngeal,
505 throat, and saliva swabs among symptomatic individuals with COVID-19. *European*
506 *Journal of Clinical Microbiology and Infectious Diseases*, 3–8.
507 <https://doi.org/10.1007/s10096-021-04202-9>
- 508 **Strömer**, A., Rose, R., Schäfer, M., Schön, F., Vollersen, A., Lorentz, T., ...
509 Krumbholz, A. (2021). Performance of a point-of-care test for the rapid detection of
510 sars-cov-2 antigen. *Microorganisms*, 9(1), 1–11.
511 <https://doi.org/10.3390/microorganisms9010058>
- 512 **Wagenhäuser**, I., Knies, K., Rauschenberger, V., Eisenmann, M., McDonogh, M.,
513 Petri, N., ... Krone, M. (2021). Clinical performance evaluation of SARS-CoV-2 rapid
514 antigen testing in point of care usage in comparison to RT-qPCR. *EBioMedicine*, 69,
515 103455. <https://doi.org/10.1016/j.ebiom.2021.103455>
- 516 **World Health Organization** (WHO; 11 September 2020). Antigen-detection in the
517 diagnosis of SARS-CoV-2 infection using rapid immunoassays: Interim guidance.
518 [WHO/2019-nCoV/Antigen_Detection/2020](https://www.who.int/publications/i/item/WHO/2019-nCoV/Antigen_Detection/2020).

519 **Acknowledgements**

520 We thank Helena Kettern, Vincent T. Jaschinski and Larissa Karl for their flexible
521 help with AgPOCT image acquisition. Furthermore, we thank M. Krogemann for help
522 with AgPOCT result scoring. Additionally, we thank M. Meurer for helpful